A novel therapeutic option for HER2-positive extramammary Paget disease

The research article presents a comprehensive evaluation of the human epidermal growth factor receptor 2 (HER2) status in extramammary Paget disease (EMPD) and explores the therapeutic potential of disitamab vedotin (DV), a novel humanized anti-HER2 antibody-drug conjugate (ADC), for this rare adenocarcinoma.

Pharma casts a wide net to hook opportunities in metabolic disorders – Pharmaceutical Technology

Pharma companies are exploring ways to investigate their assets in several metabolic disease areas. Credit: Farknot_Architect via Getty Images As Eli Lilly and Novo Nordisk

August 6, 2024

EU committee recommends AstraZeneca’s Wainzua for ATTRv-PN

ATTRv-PN is a progressive disease that causes peripheral nerve damage and motor disability. Credit: Olena Yakobchuk/Shutterstock. The European Union’s Committee for Medicinal Products for Human

October 22, 2024

(UI) Health Care Deploys Nabla’s Ambient AI Asst. Across Enterprise

What You Should Know: – Nabla, the leading ambient AI assistant for clinicians, today announced University of Iowa (UI) Health Care, Iowa’s only comprehensive academic health

September 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.